Motor Neurone Disease Trial, Recruiting NCT05983211 Sponsor: Sunnybrook Health Sciences Centre Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT05983211
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ALS (also called Lou Gehrig's disease) based on the 2020 Gold Coast diagnostic guidelines
  • You are 18 years of age or older
  • You are able to understand and agree to the study procedures and treatments on your own
  • You are allowed to be currently taking or planning to start standard ALS medications, such as riluzole (by mouth) or edaravone (by mouth or through an IV)
  • You are able to lie flat on your back without a breathing support machine (BiPAP) and without breathing discomfort for at least one hour
  • You do not have any of the listed reasons that would make the brain stimulation procedure (TMS) unsafe for you (see exclusion list below for details)
  • If you take certain medications that can affect the brain stimulation measurements (such as sleep aids, muscle relaxants, or antidepressants), you have been on a stable dose for at least 30 days before your first visit, or you have stopped taking them for at least 2 weeks beforehand

Who may not be able to join:

  • You have been diagnosed with dementia
  • You are pregnant or think you might be pregnant (if applicable)
  • You have a known allergy to the gel used with standard brain monitoring electrode pads
  • You are unable to tolerate the brain stimulation (TMS) procedure
  • You have not had a brain MRI done before joining, or you are unable to have an MRI done because of breathing difficulties when lying flat
  • Your body size makes it uncomfortable to fit inside the MRI scanner
  • You have difficulty lying still for up to one hour, or you experience significant claustrophobia (fear of enclosed spaces)
  • You have metal implants in your body that are not safe for use in an MRI scanner
  • You have previously received repetitive TMS (rTMS) treatment for any reason, as this could affect the study results
  • You have raised pressure in your skull, a growth in your brain, a history of seizures (except those caused by a specific medical treatment called ECT, or a fever-related seizure in early childhood), or significant head injury with evidence of brain blood vessel damage on a scan
  • You have a metal implant inside or near your head (not including dental work in your mouth) that cannot be safely removed
  • You have significantly abnormal blood test results, in the opinion of the study doctors
  • You are currently taking more than a certain amount of sedative medication (equivalent to more than 2 mg of lorazepam per day) or any anti-seizure medication, as these may reduce how well the treatment works
  • You have any other health condition that the study doctor believes would put you at increased risk or prevent you from completing the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Agessandro Abrahao, Dr., Sunnybrook Health Sciences Centre; University of Toronto

Phone: (416) 480-6100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 May 2024
Est. completion
15 April 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Safety and Feasibility of cTBS rTMS in patients with ALS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov